BridgeBio Pharma LLC

BridgeBio Pharma LLC is a declared insider of Eidos Therapeutics, Inc., with filings sourced from SEC (Form 4). Between 22 June 2018 and 10 December 2018, the trades on record add up to 15 filings.

In open-market terms, that means 8 purchases worth €53.6M on one side and 5 sales worth €1.4M on the other. Netting one side against the other leaves €52.2M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant.

The median purchase comes to €452k. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 13 December 2018, the filings show an open-market purchase worth €33k in Eidos Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.